Gabelli analyst Kevin Kedra reiterated a Hold rating on Nabriva Therapeutics AG (NASDAQ: NBRV) after the company announced that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE